PharmaMénta Aps
APSActiveCVR 25615697Håndværkervej 32, 6710 Esbjerg VWholesale of pharmaceutical and medical goods· NACE 4646Est. 2000 · 26 years old2 employees
Loading company…
Overview
PharmaMénta Aps is a Danish APS based in Esbjerg V, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2000, the company has 2 employees and reported a gross profit of DKK 5.2m in its latest annual filing.
Gross profit 2025
5.2M DKK
+8% vs 2024
EBITDA margin (of gross profit)
71.4 %
+8% vs 2024
Net profit 2025
2.4M DKK
+11% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
21.6 %
WeakAmong the 40% lowest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.0×
WeakAmong the 30% lowest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
10.0 %
StrongAmong the 30% highest rated companies in the industry
20212025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Gross profit | 5.2M DKK | +8% |
| EBITDA | 3.7M DKK | +8% |
| Net profit | 2.4M DKK | +11% |
| Total assets | 23.7M DKK | +19% |
| Equity | 5.1M DKK | +86% |
| Employees | 2 | — |
Company information
Legal name
PharmaMénta Aps
CVR number
25615697
Legal form
Anpartsselskab
NACE code
Founded
15 September 2000 · 26 years
Share capital
DKK 200,000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsen eller direktøren.
Company purpose
Selskabets formål er at drive handelsvirksomhed.
(no translation available)
Contact
Address
Håndværkervej 32, 6710 Esbjerg V
Phone
+45 7612 3375
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), PharmaMénta Aps reported a gross profit of DKK 5.2m, an increase of 8% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 2.4m, and the EBITDA margin stood at 71.4%.
At the end of 2025, equity financed 21.6% of the balance sheet, and current assets covered short-term debt 1 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | 5,249 | 4,868 | 1,940 | 1,720 | 2,656 |
| Staff expenses | -1,340 | -1,266 | -1,198 | -1,120 | -997 |
| EBITDA | 3,748 | 3,460 | 594 | 484 | 1,660 |
| Depreciation & amort. | -193 | -234 | -205 | -176 | -115 |
| EBIT | 3,555 | 3,226 | 389 | 309 | 1,545 |
| Net financials | -499 | -490 | -368 | -273 | -175 |
| Profit before tax | 3,056 | 2,736 | 21 | 36 | 1,370 |
| Tax | 691 | 615 | 15 | 16 | 127 |
| Net profit | 2,365 | 2,121 | 6 | 20 | 1,242 |
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 23,736 | 19,961 | 18,842 | 17,455 | 19,208 |
| Equity | 5,130 | 2,765 | 644 | 638 | 918 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 18,606 | 17,196 | 18,198 | 16,817 | 18,290 |
| Total debt | 18,606 | 17,196 | 18,198 | 16,817 | 18,290 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
71.4 %
20212025
Equity ratio
21.6 %
WeakAmong the 40% lowest rated companies in the industry
20212025
Return on equity
46.1 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Net profit margin (of gross profit)
45.1 %
20212025
Asset turnover (of gross profit)
0.22×
20212025
Debt / equity
3.63×
Very weakAmong the 20% lowest rated companies in the industry
20212025
Sector performance
23 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very strong
Among the 20% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Strong
Among the 30% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very strong
Among the 20% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 30% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery strong
Among the 10% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 30% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery weak
Among the 10% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioStrong
Among the 30% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 40% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 40% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 20% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 20% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtStrong
Among the 40% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtStrong
Among the 40% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageStrong
Among the 40% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtWeak
Among the 40% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginStrong
Among the 30% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalStrong
Among the 30% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtWeak
Among the 40% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JJ Chief Executive Officer | Chief Executive Officer | 2019 |
Former (5)
TH Management | Management | 2008 – 2019 |
SS Management | Management | 2000 – 2001 |
CE | Audit | 2000 – 2001 |
SE Audit | Audit | 2001 – 2012 |
NM Management | Management | 2007 – 2008 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TH Board of Directors | Board of Directors | 2004 |
JJ Board of Directors | Board of Directors | 2019 |
LH Chairman | Chairman | 2012 |
Former (4)
TK Board of Directors | Board of Directors | 2012 – 2019 |
MT Board of Directors | Board of Directors | 2004 – 2009 |
JM Chairman | Chairman | 2004 – 2012 |
JH Board of Directors | Board of Directors | 2009 – 2012 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 2001 | |
| Company | 25–33.32% | 25–33.32% | 2019 | |
| Company | 25–33.32% | 25–33.32% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Related companies
Company hierarchy
LHK Holding Esbjerg ApS
PharmaMénta Aps Board network connections
Board members of PharmaMénta Aps also hold positions in 35 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steen Schierbeck | Management | 10 companiesMany roles |
| Torben Hvingelby Pedersen | Management | 8 companiesMany roles |
| Lasse Hvingelby Kikkenborg | Chairman | 4 companies |
| Jimmi Javed Christensen Malik | Chief Executive Officer | 3 companies |
| Max Terpager | Board of Directors | 3 companies |
| Jørgen Makholm | Chairman | 3 companies |
| Carl Edvard Gudbergsen | Audit | 1 company |
| Svend Erik Jespersen | Audit | 1 company |
| Nina Margrethe Egtved Knudsen | Management | 1 company |
| Tom Krongaard Thomsen | Board of Directors | 1 company |
Frequently asked questions
What is the CVR number of PharmaMénta Aps?
PharmaMénta Aps is registered with CVR / Virk under CVR 25615697.
What is the gross profit of PharmaMénta Aps?
PharmaMénta Aps reported a gross profit of DKK 5.2m in 2025.
How many employees does PharmaMénta Aps have?
PharmaMénta Aps employs 2 people as of the latest annual report.
Who is the CEO of PharmaMénta Aps?
Jimmi Javed Christensen Malik is the CEO of PharmaMénta Aps, in role since 2019.
Who is the chairman of PharmaMénta Aps?
Lasse Hvingelby Kikkenborg chairs the board of PharmaMénta Aps, in role since 2012.
Where is PharmaMénta Aps headquartered?
PharmaMénta Aps's registered address is Håndværkervej 32.